Optimising microalgal lipid productivity for biodiesel production

The purpose of this work was to identify promising microalgal species and strategies of nitrogen deprivation that optimise lipid productivity for biodiesel production. This was carried out by I) developing the tools necessary to measure lipid productivity accurately, II) identifying and quantifying the key characteristics of promising microalgal strains, initially through a literature survey and then experimentally, and III) investigating the effect of different degrees of N limitation, and different N culture regimes, on cell physiology and lipid productivity in Chlorella vulgaris

Social marketing for a farmer’s market in an underserved community: A needs assessment

The aim of the present paper is to assess local residents’ awareness of utilizing Supplemental Nutrition Assistance Program (SNAP) benefits to purchase fresh produce at local farmers’ markets, and to determine internet use and media preferences of study participants prior to implementation of a social marketing campaign. A needs assessment was conducted to collect baseline data in an underserved neighbourhood in New Orleans (LA, USA). The study was carried out August 2014-May 2015. The assessment revealed that 73% of the respondents were unaware that the SNAP benefits could be used to purchase food in farmers’ markets; 63% of low-income participants never attended a farmers’ market compared to 27% of mid/high-income. Over 50% of the low-income respondents have access to the internet at least once per day. The results show the potential of raising awareness among a wide range of members in the community. This needs assessment will serve as the foundation for a social marketing intervention, which will be disseminated city-wide

Transmission of Human and Macaque Plasmodium spp. to Ex-Captive Orangutans in Kalimantan, Indonesia

We identified 4 discrete Plasmodium spp. sequences from the blood of orangutans, including 1 of P. vivax, which has implications for human residents and orangutan rehabilitation programs

Sexualisation, or the queer feminist provocations of Miley Cyrus

Miley Cyrus has increasingly occupied debates at the centre of feminist engagements with popular culture. Evoking concerns around young women and ‘sexualisation’, Cyrus emerges as a convergent signifier of sexualised media content and the girl-at-risk. As Cyrus is repeatedly invoked in these debates, she comes to function as the bad object of young femininity. Arguing, however, that Cyrus troubles the sexualisation thesis in the provocations of her creative practice, I suggest that this contested media figure exceeds the frames through which she is read. Thus, I ask: what kinds of insights might be possible if we were to transform the terms on which we approach this figure? Considering a selection of the images and performances that constitute the Cyrus archive, this article proposes a reading of Cyrus as performative provocation. Mobilising an existing sensibility of queer feminist struggle, Cyrus emerges as a disruptive, albeit contradictory, figure. Questions of privilege, limit and possibility emerge in this discussion, as well as what constitutes feminist struggle

Banner News

https://openspace.dmacc.edu/banner_news/1229/thumbnail.jp

Banner News

https://openspace.dmacc.edu/banner_news/1230/thumbnail.jp

Facet-joint injections for people with persistent non-specific low back pain (FIS) : study protocol for a randomised controlled feasibility trial

BACKGROUND: The role of injections of therapeutic substances into the back as treatment for low back pain is unclear. Facet joint injections are widely used despite the absence of evidence of sustained benefit. We hypothesise that facet joint injections might facilitate engagement with physiotherapist-led, best usual care (a combined physical and psychological programme) and is a clinically and cost-effective treatment for people with suspected low back pain of facet joint origin. METHODS/DESIGN: We present here the protocol for a randomised controlled feasibility trial for a main trial to test the above hypotheses. Patients referred to secondary care with persistent non-specific low back pain will be screened and invited to take part in the study. Those who meet the eligibility criteria will be invited for a physiotherapy assessment to confirm trial eligibility and for baseline data collection. All participants (n = 150) will be offered the best usual care package with physical and psychological components. Those randomised into the intervention arm (n = 75) will, in addition, receive intra-articular facet joint injections with local anaesthetic and steroids. Primary outcome data will be collected using daily and then weekly text messaging service for a pain score on a 0-10 scale. Questionnaire follow-up will be at 3, 6, and 12 months. Evaluation of trial processes and health economic analyses, including a value of information analysis, will be undertaken. The process evaluation will be mixed methods and will include the views of all stakeholders. DISCUSSION: Whilst this trial is a feasibility study it is currently one of the largest trials in this area. The outcomes will provide some evidence on the use of facet joint injections for patients with clinically diagnosed facet joint pain. TRIAL REGISTRATION: EudraCT identifier 2014-000682-50

Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis : Results from Greater Than 17,000 Patient-Years of Exposure

Altres ajuts: The studies described herein and the Rapid Service Fee were funded by Eli Lilly and Company.Long-term safety data are critical for evaluating therapies for psoriasis. Ixekizumab has demonstrated efficacy and is well tolerated for the treatment of moderate-to-severe plaque psoriasis. We examined the safety and tolerability of up to 5 years of ixekizumab therapy in patients with psoriasis. Integrated safety data were analyzed from 13 ixekizumab clinical studies. Rates of treatment-emergent adverse events (TEAEs), serious AEs (SAEs) and AEs of special interest were analyzed for the 12-week induction period in the combined pivotal studies, and for all pooled studies by year(s) of therapy and overall, reported as exposure-adjusted incidence rates (IRs) per 100 patient-years (p-y) and/or frequencies. Total ixekizumab exposure was 17,003.4 p-y (N = 5898); 2749 patients had ≥ 4 years of exposure. When compared across years of exposure, rates for AEs remained largely stable or declined, including TEAEs leading to discontinuation (3.8/100 p-y in year 1, declining to 2.0/100 p-y in year 5); SAEs (range 6.2-7.0/100 p-y); serious infections (range 1.3-1.7/100 p-y); nonmelanoma skin cancer (ranging from 0.5/100 p-y in year 1 to 0.2/100 p-y in years 4-5); other malignancies (range 0.4-0.6/100 p-y); inflammatory bowel disease including ulcerative colitis and Crohn's disease (IR 0.2/100 p-y); and major adverse cardiovascular events (MACE) (range 0.3-0.7/100 p-y). Candidiasis was reported in 327 patients (IR 1.9/100 p-y), with the majority identified as mucocutaneous. The rate of injection site reactions was 15.5/100 p-y during year 1 and 2.0-2.3/100 p-y by years 3-5. The decrease in rates of TEAEs and the stable rates of SAEs, other malignancies and MACE during up to 5 years of ixekizumab dosing are consistent with previous reports describing a favorable safety profile of ixekizumab following shorter durations of exposure. Eli Lilly and Company

Book reviews

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/46102/1/168_2005_Article_BF01287326.pd